MedPath

gamma-Hydroxybutyric acid

Generic Name
gamma-Hydroxybutyric acid
Brand Names
Xywav
Drug Type
Small Molecule
Chemical Formula
C4H8O3
CAS Number
591-81-1
Unique Ingredient Identifier
30IW36W5B2

Overview

Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Background

Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Indication

Used as a general anesthetic, to treat conditions such as insomnia, clinical depression, narcolepsy, and alcoholism, and to improve athletic performance.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase 2
Not yet recruiting
Posted: 2025/04/30
Sponsor:
Leiden University Me...
Phase 2
Not yet recruiting
Posted: 2024/05/20
Sponsor:
Leiden University Me...
Phase 4
Completed
Posted: 2021/10/20
Sponsor:
Centre Hospitalier I...

FDA Approved Products

XYWAV
Manufacturer:Jazz Pharmaceuticals, Inc.
Route:ORAL
Strength:0.5 g in 1 mL
Approved: 2022/03/10
NDC:68727-150
XYWAV
Manufacturer:Jazz Pharmaceuticals, Inc.
Route:ORAL
Strength:0.5 g in 1 mL
Approved: 2022/03/10
NDC:68727-150
XYWAV
Manufacturer:Jazz Pharmaceuticals, Inc.
Route:ORAL
Strength:0.5 g in 1 mL
Approved: 2022/03/10
NDC:68727-150

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath